TCGA-AR-A24W-01A-11R-A169-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 52
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20020070.LumA | — | A | 0.874 |
| 2 | SRR35579842 | — | A | 0.864 |
| 3 | 20020009.LumA | — | A | 0.856 |
| 4 | SRR8613790 | — | A | 0.850 |
| 5 | TCGA-97-7938-01A-11R-2170-07 | — | cohortA1 | 0.837 |
| 6 | TCGA-A1-A0SH-01A-11R-A084-07 | — | A | 0.836 |
| 7 | TCGA-D8-A146-01A-31R-A115-07 | — | A | 0.835 |
| 8 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.832 |
| 9 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.831 |
| 10 | TCGA-AN-A0XL-01A-11R-A10J-07 | — | A | 0.822 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.500 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |